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9V (15.3%), 4 (9%), 3 (6.9%), 8 (5.6%), 12B (4.9%)
and 5 (4.9%) being the most common [15]. Only
four serotypes were represented among the peni-
cillin-non-susceptible isolates, namely 9V (74%),
14 (14.8%), 23F (7.4%) and 6B (3.7%). Only 11%
of all isolates belonged to serotypes not included
in the 23-valent non-conjugated polysaccharide
vaccine, but some protection may be afforded by
cross-reactivity between serotypes [15].
In conclusion, the prevalence of isolates non-
susceptible to penicillin in Ireland is worryingly
high, but all isolates are currently susceptible to
cefotaxime, moxifloxacin and linezolid. Patients
in Ireland with invasive pneumococcal infections
should continue to receive cefotaxime as empir-
ical treatment. Should cefotaxime resistance
emerge, the extended-spectrum fluoroquinolones
and linezolid may be useful alternatives.
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A B S T R A C T
An isolate of Streptococcus pyogenes isolated from a
63-year-old woman with a serious wound infection
wasfoundtobehighlyresistant tofluoroquinolones
(levofloxacin MIC ‡ 32 mg ⁄L). DNA amplification
and sequencing revealed a serine-81 to phenylalan-
ine substitution in gyrA and three substitutions in
parC: serine-79 to phenylalanine, aspartic acid-91 to
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asparagine, and serine-140 to proline. To our know-
ledge, this is the first report from a European
country of a clinical isolate of S. pyogenes with
high-level fluoroquinolone resistance.
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Streptococcus pyogenes has remained fully suscept-
ible to penicillin G, the preferred treatment for
patients with S. pyogenes infections, but erythro-
mycin-resistant isolates of S. pyogenes have been
reported increasingly from different parts of the
world. Fluoroquinolones (e.g., levofloxacin, mox-
ifloxacin and gatifloxacin) with improved activity
against Gram-positive bacteria are now used
widely in Germany. Resistance to these com-
pounds in streptococci has been reported in only
a very few pneumococcal isolates [1]. Surveillance
data from Germany have indicated that S. pyogenes
isolates are sensitive to newer fluoroquinolones
[2], and, to our knowledge, only two strains of
S. pyogenes with high-level fluoroquinolone resist-
ance have been reported previously, both from the
USA [3,4]. The present report describes the isola-
tion and characterisation of a highly levofloxacin-
resistant strain of S. pyogenes from Germany.
As part of a nationwide surveillance study
involving 381 isolates of S. pyogenes from outpa-
tients, the resistant strain (MSR 141) was isolated
in 2000 from the wound of a 63-year-old woman
in Bavaria, in the south of Germany. Data on
previous antibiotic therapy were not available.
The isolate was identified by haemolysis on sheep
blood agar, Lancefield (A) grouping with com-
mercially available agglutination reagents (Slidex,
Streptokit; bioMe´rieux, Marcy-L’Etoile, France),
and a positive pyrrolidonyl-arylamidase test.
MICs were determined by the broth microdi-
lution method [5] using cation-adjusted Mueller–
Hinton broth (Oxoid, Wesel, Germany) contain-
ing lysed horse blood (Oxoid) 3% v ⁄ v, with a
final inoculum of 5 · 105 CFU ⁄mL and incubation
at 35C for 24 h in ambient air. S. pneumoniae
ATCC 49619 was used as a control strain. Emm
typing was performed as described by Podbielski
et al. [6]. Similarity searching was performed
using the N-terminal hypervariable region of the
M gene, based on the latest information from the
Centers for Disease Control website (http://
www.cdc.gov/ncidod/biotech/strep/emmtypes.
htm). S. pyogenes CS101 (M type 49) was used as a
reference strain. Multilocus sequence typing was
performed as described by Enright et al. [7], using
internal fragments of the glucose kinase (gki),
glutamine transporter protein (gtr), glutamate
racemase (murI), DNA mismatch repair protein
(mutS), transketolase (recP), xanthine phosphorib-
osyltransferase (xpt), acetyl coenzyme A (acetyl-
CoA) and acetyltransferase (yqiL) genes. T typing
was performed as described by Brandt et al. [8].
Mutations in the quinolone resistance deter-
mining regions of gyrA and parC were investi-
gated by PCR with chromosomal DNA as
template and subsequent DNA sequencing. Prim-
ers (5¢-GCAAGATCGAAATTTAATTGACGTC-3¢
(nucleotides 3–27) and 5¢-ACTCTCTTGTTGTA
CAGTCTGG-3¢ (nucleotides 595–616) were used
to amplify a 614-bp fragment of gyrA, and primers
5¢-ATGTCAAACATTCAAAACATGTCC-3¢ (nu-
cleotides 1–24) and 5¢-AGCCTGCGGAAATAC
CAGAAG-3¢ (nucleotides 500–520) were used to
amplify a 520-bp fragment of parC [4]. PCR
conditions were as described by Yan et al. [4].
Isolate MSR 141 was sensitive to penicillin G
(MIC 0.016 mg ⁄L), cefotaxime (MIC 0.016 mg ⁄L),
amoxycillin (MIC 0.016 mg ⁄L), erythromycin A
(MIC 0.06 mg ⁄L), clindamycin (MIC 0.06 mg ⁄L),
telithromycin (MIC 0.016 mg ⁄L) and tetracycline
(MIC 0.25 mg ⁄L), but was highly resistant to
levofloxacin (MIC ‡ 32 mg ⁄L), ciprofloxacin
(MIC ‡ 32 mg ⁄L), grepafloxacin (MIC ‡ 32 mg ⁄L)
and sparfloxacin (MIC ‡ 32 mg ⁄L), with elevated
MICs of gatifloxacin (MIC 4 mg ⁄L), moxifloxacin
(MIC 4 mg ⁄L) and clinafloxacin (MIC 0.5 mg ⁄L).
DNA amplification and sequencing revealed a
serine-81 to phenylalanine substitution in gyrA,
and three substitutions in parC: serine-79 to phe-
nylalanine, aspartic acid-91 to asparagine, and
serine-140 to proline. Emm typing showed that
MSR 141 belonged to emm89 (T type: B3264).
Multilocus sequence typing showed the following
allelic profile: gki 16, gtr 2, murL 8, mutS 3, recP 1,
xpt13, yqiL 3) (sequence type 101). Table 1 provides
a comparison of the data for MSR 141 with the data
for the two highly resistant isolates of S. pyogenes
reported previously from the USA [3,4].
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Fluoroquinolone resistance usually results
from mutations in the quinolone resistance
determining regions of either gyrA or parC, or
both genes, particularly at the highly conserved
serine-81 (gyrA) and serine-79 (parC) residues, as
reported for quinolone resistance in Streptococcus
pneumoniae [1,9]. The present study reports the
first highly fluoroquinolone-resistant S. pyogenes
isolate from Europe. To our knowledge, only
two previous reports, both from the USA, of
highly fluoroquinolone-resistant S. pyogenes
strains have been published [3,4] (Table 1). The
serine-140 and aspartic acid-91 alterations in
strain MSR 141 from Germany have not been
described previously [9] and require further
investigation.
S. pyogenes isolates with low-level resistance to
ciprofloxacin have been reported in other Euro-
pean surveillance studies. Latorre et al. [10] ana-
lysed 226 isolates from Spain with ciprofloxacin
MICs ‡ 2 mg ⁄L. MIC ranges were 0.5–8 mg ⁄L for
ofloxacin, 0.06–4 mg ⁄L for levofloxacin, 0.03–
8 mg ⁄L for sparfloxacin, 0.03–2 mg ⁄L for gatifl-
oxacin, 0.015–1 mg ⁄L for moxifloxacin and 0.008–
0.5 mg ⁄L for gemifloxacin [10]. In addition,
Alonso et al. [11] investigated low-level resistance
to fluoroquinolones in a single S. pyogenes isolate
from Spain [11]. This isolate had a base-pair
change (TCC ⁄GCC) at position 336 in the parC
gene that resulted in the amino-acid substitution
Ser79Ala. No mutations in the quinolone resist-
ance determining region of gyrA were detected.
No such isolate has yet been observed in surveil-
lance studies performed in Germany [2,12] but, as
documented for the macrolides [13], increased use
of fluoroquinolones in outpatients may be driving
resistance. For Germany, a linear increase of
fluoroquinolone usage in outpatients has been
observed, from 2.2 million packages in 1991 to 7
million packages in 2001 (M. Kresken, personal
communication).
Polyclonal spread of resistant clones is well-
documented as making a major contribution to
the overall spread of fluoroquinolone resistance in
Gram-positive bacteria in many countries [14].
Analysis of pathogenicity markers showed that
MSR 141 has the potential for spread. Isolates of
emm type 89 are usually T11 ⁄ 12 and opacity
factor-positive, but significant numbers of isolates
are T3 ⁄ 13 ⁄B3264. This emm type is found in
Germany in 5–10% of cases of invasive and
non-invasive disease (R. R. Reinert, unpublished
data). Similar strains have been reported from the
USA, Egypt, Brazil, Argentina, Chile, Mexico,
Nepal (skin lesion isolates from children) and
Italy [2,12]. Sequence type 101 is observed rarely,
and only one other strain (an emm89, fluoroqui-
nolone-susceptible strain isolated from a case of
pharyngitis in Italy during 2000) exists in the
multilocus sequence typing data base.
In conclusion, this report of the first European
isolate of S. pyogenes with high-level fluoroquino-
lone resistance is another reminder that the new
fluoroquinolones should be used appropriately.
Given the uniform activity of b-lactams against
S. pyogenes, the b-lactam antibiotics should remain
the preferred treatment for S. pyogenes infections.
Fluoroquinolone resistance in S. pneumoniae is
now reported increasingly, especially from Asia,
but remains very uncommon in Europe [15].
Fluoroquinolone resistance in S. pyogenes is cur-
rently extremely rare in Europe [12] and is not a
clinical problem, but continuous surveillance of
the level of resistance is necessary.
Table 1. Characteristics of three Streptococcus pyogenes strains showing high-level resistance to fluoroquinolones
Country Source
MICs (or susceptibility) Emm
type ⁄T
type
Amino-acid
alteration in
QRDR
ReferencePEN ERY CLI LEV GAT GREP MOX CIP CLINA gyrA parC
Germanya Wound £ 0.016b 0.06b 0.06b ‡ 32 4 ‡ 32 4 ‡ 32 0.5 89 ⁄B3264 S81F S79F,
S140P,
D91N
This report
USA Blood £ 0.016b £ 0.25b £ 0.25b 16 4 ND 2 32 ND 12 ⁄ nt S81Y S79F,
A121V
[3]
USA Blood S S S ‡ 32 ND ‡ 32 ND ‡ 32 1 ND S81F,
M99V
S79Y [4]
aIsolate MSR 141.
bSusceptible.
CIP, ciprofloxacin; CLI, clindamycin; CLINA, clinafloxacin; ERY, erythromycin A; GAT, gatifloxacin; GREP, grepafloxacin; LEV, levofloxacin; MOX, moxifloxacin; ND, no
data; nt, non-typeable; PEN, penicillin G; QRDR, quinolone resistance determining region; S, susceptible.
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The relationship between resistance to rifampicin
and rifabutin and genetic alterations in the rpoB
gene of 41 rifampicin-resistant isolates of Myco-
bacterium tuberculosis was evaluated. Although 35
isolates with rifampicin MICs ‡ 32 mg ⁄L were
also rifabutin-resistant, six isolates with rifampi-
cin MICs of 2–16 mg ⁄L were susceptible to rifabu-
tin (MIC £ 0.5 mg ⁄L). Mutations Asp516Val,
Asp516Tyr, Leu533Pro and the double mutation
Met515Ile and Leu533Pro influenced susceptibil-
ity to rifampicin, but not to rifabutin. All muta-
tions at codons 531 and 526, except one isolate
with a His526Cys mutation, correlated with resist-
ance to both compounds.
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Multidrug-resistant Mycobacterium tuberculosis
isolates have been described worldwide, and
their existence poses a serious threat to tubercu-
losis control programmes in many countries [1,2].
The development of more active and safe anti-
tuberculosis agents as alternatives to rifampicin
and isoniazid is therefore a high priority [3,4].
DNA sequencing studies demonstrate that > 90%
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